PARSIPPANY, N.J. & TOKYO, Japan--(BUSINESS WIRE)-- The Medicines Company (MDCO) and SymBio Pharmaceuticals Ltd. (4582:Tokyo), a Tokyo based specialty pharmaceutical company, today announced the ...
Copyright 2020 FactSet Research Systems Inc. All rights reserved. Source: FactSet Fundamentals Stocks: Real-time U.S. stock quotes reflect trades reported through ...
Multikinase inhibitor rigosertib is currently in clinical development against both MDS and solid tumors. SymBio Pharmaceuticals negotiated rights to develop Onconova Therapeutics’ rigosertib (Estybon ...
SymBio Pharmaceuticals Ltd. engages in the pharmaceutical business. It researches, develops, manufactures, and sells new drugs focusing on the areas of oncology, hematology, and autoimmune diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results